- L243 (See other available formats)
- Regulatory Status
- Other Names
- Major Histocompatibility Class II, MHC class II
- Mouse IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Check Availability||Save|
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.Product Details
- Human, African Green, Baboon, Chimpanzee, Cynomolgus, Dog (Canine), Marmoset, Rhesus, Squirrel Monkey, Tamarin
- Antibody Type
- Host Species
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 570™ under optimal conditions.
- Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Brilliant Violet 570™ excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 570™ is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet™.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
- Excitation Laser
Violet Laser (405 nm)
- Application Notes
The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the aß heterodimer.19
Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7, and immunohistochemical staining of acetone-fixed frozen sections4,5. For sensitive functional assays, we recommend using the Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 307648, 307665 - 307669).
- Application References
- Brodsky F. 1984. Immunogenetics 19:179.
- Robbins P, et al. 1987. Human Immunol. 18:301.
- Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
- Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
- Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
- Zipf T, et al. 1981. Cancer Res. 41:4786.
- Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
- Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
- Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
- Wang RF, et al. 1999. Science 284:1351. (Block)
- Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
- Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
- Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
- Stein R, et al. 2011. Leuk. Lymphoma 52:273.
- Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
- Moro M, et al. 2005. BMC Immunol. 6:24.
- Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
- Product Citations
AB_10895753 (BioLegend Cat. No. 307637)
AB_2650882 (BioLegend Cat. No. 307638)
- Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs
- Peptide presentation
- CD3/TCR, CD4
- Cell Type
- Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
- Biology Area
- Immunology, Innate Immunity
- Molecular Family
- MHC Antigens
- Antigen References
1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.
- Gene ID
- 3122 View all products for this Gene ID 3123 View all products for this Gene ID
- View information about HLA-DR on UniProt.org
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.